Oncobiologics (NASDAQ:OTLK – Get Free Report) and Tango Therapeutics (NASDAQ:TNGX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
Risk and Volatility
Oncobiologics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Valuation & Earnings
This table compares Oncobiologics and Tango Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncobiologics | $1.35 million | 160.70 | -$62.42 million | ($1.17) | -1.25 |
| Tango Therapeutics | $62.38 million | 64.09 | -$101.59 million | ($0.83) | -33.30 |
Oncobiologics has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Oncobiologics and Tango Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncobiologics | N/A | N/A | -291.28% |
| Tango Therapeutics | N/A | -41.54% | -33.44% |
Analyst Recommendations
This is a summary of current ratings and target prices for Oncobiologics and Tango Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncobiologics | 1 | 5 | 1 | 0 | 2.00 |
| Tango Therapeutics | 1 | 2 | 13 | 0 | 2.75 |
Oncobiologics currently has a consensus target price of $6.50, suggesting a potential upside of 345.21%. Tango Therapeutics has a consensus target price of $41.85, suggesting a potential upside of 51.40%. Given Oncobiologics’ higher possible upside, research analysts clearly believe Oncobiologics is more favorable than Tango Therapeutics.
Insider and Institutional Ownership
11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Tango Therapeutics beats Oncobiologics on 8 of the 13 factors compared between the two stocks.
About Oncobiologics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
About Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
